Supernus Pharmaceuticals Inc (SUPN)
32.29
-0.13
(-0.40%)
USD |
NASDAQ |
Mar 28, 16:00
32.28
-0.02
(-0.05%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 1.802B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -5.34% |
| Valuation | |
| PE Ratio | 24.42 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 2.730 |
| Price to Book Value | 1.740 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 75.86% |
Profile
Edit
| Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
| URL | https://www.supernus.com |
| Investor Relations URL | https://ir.supernus.com/ |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | May. 08, 2025 (est.) |
| Last Earnings Release | Feb. 25, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
Edit
| Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER. |
| URL | https://www.supernus.com |
| Investor Relations URL | https://ir.supernus.com/ |
| HQ State/Province | Maryland |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | May. 08, 2025 (est.) |
| Last Earnings Release | Feb. 25, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |